Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say

Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say

Source: 
Stat
snippet: 

The latest Alzheimer’s disease treatment from Eisai and Biogen needs to be cheaper than $20,000 a year to be cost-effective, according to a draft analysis from an influential nonprofit organization published Thursday.